GAITHERSBURG, Md., Jan. 21 /PRNewswire/ -- Panacea Pharmaceuticals, Inc.
is pleased to announce the appointment of Lawrence I. Glass to the position of
Chief Strategy Officer. In this new position, Mr. Glass will be responsible
for the development of strategic plans that address and integrate all major
segments of the Company including product development, operational, legal, and
financial activities.
"We are excited to appoint Larry to this important position, which has
been designed to bring critical real-time analysis, insights, forecasts, and
creativity to Panacea," stated Hossein A. Ghanbari, PhD, President & CEO of
the Company.
Mr. Glass is a manager, strategist, and scientist with more than twenty
years of experience in the life sciences industry. The primary emphasis of
his career has been on business and corporate development, building and
directing biomedical research, and drug development programs. His particular
expertise is in developing interdisciplinary programs that integrate
laboratory and clinical R&D with corporate development strategies. He also
has extensive experience in areas such as financing, mergers and acquisitions,
and technology assessment.
Mr. Glass served as Executive Vice-President for Corporate Development &
Scientific Affairs for Virco Lab, Inc., the U.S. subsidiary of Virco Group
(Belgium). Prior to that, he spent nearly twenty years at SRA Life Sciences,
Inc., which was acquired by Virco in late 2000. At SRA, Mr. Glass served as
Senior Vice-President & Director of Corporate Development and most recently as
President & CEO. He was the principal architect of SRA's biomedical business
and built an internationally recognized team conducting pharmacogenomic and
viral drug resistance testing, working with many of the top pharmaceutical and
biotechnology companies in the world.
Prior to SRA, Mr. Glass held positions at various institutions including
the National Institute for Advanced Studies, the University of Minnesota
College of Medicine, and the Minneapolis Children's Hospital and Health
Center.
Mr. Glass serves as a Director for Imperidis Corporation, a medical device
company developing novel products for post-operative and long-term care
applications.
About Panacea Pharmaceuticals
Panacea Pharmaceuticals, Inc. is an emerging biopharmaceutical company
focused on utilizing functional genomics and proteomics to develop
therapeutics and diagnostics for diseases with substantial unmet clinical
need. The Company's product development focus is on novel proteins and
biochemical pathways related to cellular regulation and cell cycle
abnormalities in oncology as well as neurodegenerative diseases, particularly
Alzheimer's disease and Parkinson's disease.
More information is available at http://www.PanaceaPharma.com .
Except for historical information presented in this press release, matters
discussed herein may constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements are based on the opinions and estimates of management only
as of the date of this release and are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance, or achievements expressed or implied by such
statements. Factors that might cause such a difference include, but are not
limited to, uncertainties related to our access to capital, the progress,
costs, and results of any clinical trials undertaken by us, progress of our
research and development projects, and uncertainties related to whether our
product candidates would ultimately achieve commercial success. We do not
undertake any obligation to update publicly any forward-looking statement,
whether as a result of new information, future events, or otherwise unless
required by law.
Contact:
Panacea Pharmaceuticals, Inc.
Kasra Ghanbari, Chief Operating Officer
Phone 240-243-8000; FAX 240-465-0450
Kasra@PanaceaPharma.com
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panaceapharma.com
CONTACT:
Kasra Ghanbari, Chief Operating Officer of
Panacea Pharmaceuticals, Inc., +1-240-243-8000, or fax,
+1-240-465-0450, or Kasra@PanaceaPharma.com
|
